The value of18F-FDG-PET/CT imaging in oral cavity cancer patients following surgical reconstruction

2015 ◽  
Vol 125 (8) ◽  
pp. 1861-1868 ◽  
Author(s):  
Julian Müller ◽  
Martin Hüllner ◽  
Klaus Strobel ◽  
Gerhard F. Huber ◽  
Irene A. Burger ◽  
...  
2013 ◽  
Vol 3 (2) ◽  
pp. S24 ◽  
Author(s):  
M. Marquardt ◽  
C.M. Anderson ◽  
S. Steen ◽  
A. Hoover ◽  
L. Karnell ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Shuailiang Wang ◽  
Xin Zhou ◽  
Xiaoxia Xu ◽  
Jin Ding ◽  
Teli Liu ◽  
...  

This study aims to further explore dynamic 68Ga-FAPI-04 PET/CT imaging of healthy Chinese subjects and lung cancer patients. Moreover, the variability of 68Ga-FAPI-04 uptake in normal organs was measured to provide a basis for analyzing its biological distribution, interpreting auxiliary images, determining the reliability of image quantification, and monitoring treatment. Six patients (3 subjects without tumors and 3 lung cancer patients) separately underwent 68Ga-FAPI-04 and 2-[18F]FDG PET/CT imaging within 1 week. The biodistribution and internal radiation dosimetry were reported and compared with data previously obtained from Caucasian patients. Moreover, the mean SUV (standardized uptake value) was normalized to body mass or to lean body mass (SUL), and the coefficients of variation (CVs) were calculated and compared for each volume of interest. The average whole-body effective dose was calculated to be 1.27E-02 mSv/MBq, which was comparable with previously reported results of 68Ga-FAPI-04 probes. Furthermore, the SUVmean was slightly higher than the SULmean in most organs; however, the CV of the SULmean for most organs was higher than that of the SUVmean at later time points. In the liver, the CV of the SUVmean was lower (12.7%) than that of the SULmean and was similar to the CV for corresponding 2-[18F]FDG PET/CT value (11.8%). In addition, 68Ga-FAPI-04 PET/CT showed good efficacy for diagnosing lung cancer patients in this study. A comparison of the radiation dosimetry obtained before from a Caucasian population demonstrated no clinically significant differences between these two populations after 68Ga-FAPI-04 injection. The variability in most organs was slightly lower for SUVmean than for SULmean, suggesting that SUVmean may be the preferable parameter for quantifying images obtained with 68Ga-FAPI-04. In addition, 68Ga-FAPI-04 PET/CT imaging is expected to be a promising tool for diagnosing lung cancer.


2016 ◽  
Vol 43 (12) ◽  
pp. 2228-2235 ◽  
Author(s):  
Jahae Kim ◽  
Kang-Ho Choi ◽  
Ho-Chun Song ◽  
Joon-Tae Kim ◽  
Man-Seok Park ◽  
...  

2008 ◽  
Vol 49 (9) ◽  
pp. 1422-1428 ◽  
Author(s):  
C.-H. Baek ◽  
M. K. Chung ◽  
Y.-I. Son ◽  
J. Y. Choi ◽  
H.-J. Kim ◽  
...  

2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 123-123
Author(s):  
Gary Schnur ◽  
Katherine Glass ◽  
Chad W Cummings ◽  
Alberto J. Montero ◽  
Jame Abraham ◽  
...  

123 Background: The Cleveland Clinic is utilizing disease specific teams to craft care paths for value based disease management. The report by Groheux (JNCI 2012; 104:1879-1887), reported 18 FDG-PET-CT detected distant metastasis in 10.7, 17.5 and 36.5% of stage IIB- IIIB breast cancer patients. Based on this report, the breast team incorporated 18 FDG-PET- CT imaging for initial staging of IIB-IIIB patients. Methods: Treatment algorithms were developed by a multi-disciplinary breast cancer team. The content was reviewed by stakeholders throughout the health system, and feedback was incorporated into the care paths as appropriate. Content was communicated using physician meetings, electronic communication, tumor boards, and operational pilots. The treatment algorithm, along with the supporting narrative, was placed on the cancer center intranet, accessible to all practicing physicians. Additional intranet analysis was performed using Google Analytics, which identifies the site location and frequency of document downloads. We retrospectively examined the impact of this posting after one year (7/2014-7/2015). Manual chart review identified new patient consults for Stage IIB-IIIB breast cancer at our main campus and highest volume regional sites. Results: PET scans were ordered in 36 stage IIB, 19 stage IIIA, and 3 stage IIIB patients. Of the 36 IIB patients scanned, occult metastatic disease was noted in 1, and 2 patients migrated to IIIA without a change in treatment. 19 IIIA patients had no change in stage, although an asymptomatic second primary lung cancer was discovered in 1 .Three stage IIIB patients were without staging change. Conclusions: PET/CT imaging did not contribute to patient management for stage IIB-IIIB breast cancer patients at our institution, unlike the results reported elsewhere. Analysis of care path metrics allows us to expediently review and adjust recommendations to affiliated physicians.


2017 ◽  
Vol 16 (4) ◽  
pp. 343-348
Author(s):  
Martin Fehr ◽  
Joachim Müller ◽  
Meinhard Knitel ◽  
Jürgen Fornaro ◽  
Daniel Horber ◽  
...  

2013 ◽  
Vol 28 (4) ◽  
pp. 252
Author(s):  
Venkatesh Rangarajan ◽  
AmeyaD Puranik ◽  
NilenduC Purandare ◽  
Sneha Shah ◽  
Archi Agrawal

2010 ◽  
Vol 52 (2) ◽  
pp. 201-206 ◽  
Author(s):  
ANDERS E. HANSEN ◽  
FINTAN MCEVOY ◽  
SVEND A. ENGELHOLM ◽  
IAN LAW ◽  
ANNEMARIE T. KRISTENSEN

Sign in / Sign up

Export Citation Format

Share Document